Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3R1 | P27986 | 12/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23778200 | 0.88 | NR1H2 (0.39) | PIK3R1PIK3CANR1H2PIK3CDPIK3CB | |
| SCHEMBL23778205 | 0.79 | ATM (0.46) | NR1H2 | |
| SCHEMBL12307411 | 0.76 | NR1H2 (0.45) | NR1H2MEN1KMT2AESR2NAMPT | |
| SCHEMBL29697602 | 0.76 | NR1H2 (0.45) | NR1H2ESR2 | |
| SCHEMBL22435395 | 0.76 | NR1H2 (0.45) | NR1H2ESR2 | |
| SCHEMBL12307412 | 0.75 | NR1H2 (0.48) | NR1H2MEN1KMT2AESR2ALDH1A1 | |
| SCHEMBL26645516 | 0.74 | NR1H2 (0.46) | NR1H2NAMPT | |
| SCHEMBL26645198 | 0.74 | NR1H2 (0.47) | NR1H2MEN1KMT2AESR2ALDH1A1 | |
| SCHEMBL24535901 | 0.74 | MEN1 (0.43) | NR1H2MEN1KMT2AESR2 | |
| SCHEMBL30793149 | 0.74 | NR1H2 (0.42) | NR1H2MEN1KMT2AESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220009931-A1 | NOVEL UREA 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2022-01-13 | — | — | US | disclosed |
| US-20220009931-A1 | NOVEL UREA 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2022-01-13 | — | — | US | disclosed |
| EP-3873907-A1 | NOVEL UREA 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AiCuris GmbH & Co. KG (DE) | 2021-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220009931-A1 | NOVEL UREA 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | HCCS, CDK2, CDKN1A | PIK3R1 2974/4885PIK3CA 2581/4885NR1H2 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.